BioSpace News Archive

New Chilmark Research report evaluates over 120 commercial AI/ML solutions in healthcare, explores future opportunities, and assesses obstacles to adoption at scale

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended December 31, 2019, and provided an update on recent accomplishments and upcoming events.

Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2019 financial results on Thursday, March 12, 2020 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to provide perspectives on its planned Phase 2 clinical trial of Brilacidin in pill form, its defensin mimetic drug candidate with multi-indication potential, as a novel oral medication for the treatment of Ulcerative Colitis (UC).

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to three new employees.

Cure Alzheimer’s Fund, a nonprofit organization dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, announced it has received a $1 million donation from Kristin Berg, Steven Berg and Laurie Berg Sapp in honor of their parents.

Aridis Pharmaceuticals, Inc. announced that Vu Truong, Ph.D., Chief Executive Officer, will present at the 32nd Annual ROTH Conference on Monday, March 16, 2020 at 4:00 pm PDT.

Since the outbreak of the novel coronavirus first emerged in January, Qiming Venture Partners’ portfolio companies have been actively taking measures to cope with the challenging situation in China.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2019, and provided recent operational highlights.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March 12, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.